Khouri, I F <br/><br/>
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.  [electronic resource] 

 -  Bone marrow transplantation  Jan 2017 
 - 28-33 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1476-5365 
<br/><br/><label>Standard No.: </label>10.1038/bmt.2016.204  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Bendamustine Hydrochloride--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--mortality<br/>Male<br/>Middle Aged<br/>Rituximab--administration & dosage<br/>Survival Rate<br/>Transplantation Conditioning--methods<br/>Vidarabine--administration & dosage